Sun Fengze, Liu Hongquan, Wu Gang, Liu Ming, Liu Shangjing, Wang Lin, Zou Qingsong, Cui Yuanshan, Wu Jitao
Department of Urology, Yantai Yuhuangding Hospital, Qingdao University, Yantai, Shandong, China.
The Second Clinical Medical College, Binzhou Medical University, Yantai, Shandong, China.
Front Pharmacol. 2024 May 30;15:1351312. doi: 10.3389/fphar.2024.1351312. eCollection 2024.
Urolithiasis is a common urological diseases and affects the daily life of patients. Medical expulsive therapy has become acceptable for many parents. We conducted a meta-analysis to determine the efficacy and safety of tadalafil compared with tamsulosin for treating distal ureteral stones less than 10 mm in length.
Related studies were identified via searches of the PubMed, Embase, and Cochrane Library databases. All the articles that described the use of tadalafil and tamsulosin for treating distal ureteral stones were collected.
A total of 14 studies were included in our meta-analysis. Our results revealed that tadalafil enhanced expulsion rate [odds ratio (OR) = 0.68, 95% confidence interval (CI): 0.47 to 0.98, = 0.04]; reduced expulsion time [mean difference (MD) = 1.22, 95% CI (0.13, 2.30), = 0.03]; lowered analgesia use [MD = 38.66, 95% CI (7.56, 69.77), = 0.01] and hospital visits [MD = 0.14, 95% CI (0.06, 0.22), = 0.0006]. According to our subgroup analysis, either tadalafil 5 mg or 10 mg did not promote expulsion rate and accelerate expulsion time compared with tamsulosin. But patients receiving 5 mg tadalafil decreased analgesia usage [MD = 101.04, 95% CI (67.56, 134.01), < 0.00001].
Compared with tamsulosin, tadalafil demonstrates a higher expulsion rate and less expulsion time for patients with distal ureteral stones less than 10 mm with a favorable safety profile.
尿石症是一种常见的泌尿系统疾病,影响患者的日常生活。药物排石疗法已为许多患者所接受。我们进行了一项荟萃分析,以确定他达拉非与坦索罗辛相比治疗长度小于10毫米的远端输尿管结石的疗效和安全性。
通过检索PubMed、Embase和Cochrane图书馆数据库来识别相关研究。收集所有描述使用他达拉非和坦索罗辛治疗远端输尿管结石的文章。
我们的荟萃分析共纳入14项研究。结果显示,他达拉非提高了排石率[比值比(OR)=0.68,95%置信区间(CI):0.47至0.98,P=0.04];缩短了排石时间[平均差(MD)=1.22,95%CI(0.13,2.30),P=0.03];减少了镇痛药物的使用[MD=38.66,95%CI(7.56,69.77),P=0.01]以及医院就诊次数[MD=0.14,95%CI(0.06,0.22),P=0.0006]。根据亚组分析,与坦索罗辛相比,5毫克或10毫克他达拉非均未提高排石率或加快排石时间。但接受5毫克他达拉非治疗的患者镇痛药物使用量减少[MD=101.04,95%CI(67.56,134.01),P<0.00001]。
与坦索罗辛相比,他达拉非对长度小于10毫米的远端输尿管结石患者具有更高的排石率和更短的排石时间,且安全性良好。